Physician profile
Fitz Martin
NPI 1972142669
$6,330.06
in general payments reported to CMS, 2019-2025
15 companies · $492 in 2025
The $492 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,898 · 2022: $2,001 · 2023: $1,374 · 2024: $565 · 2025: $492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,332 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,332.22 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $1,021.72 | 2021-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $981.32 | 2021-2023 | Invega Sustenna, Invega Trinza, Spravato |
| Teva Pharmaceuticals USA, INC. | $749.62 | 2021-2025 | Austedo Xr, Uzedy, Austedo |
| Alkermes, INC. | $716.02 | 2021-2025 | Aristada, Lybalvi |
| Abbvie INC. | $701.72 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $654.84 | 2021-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Vanda Pharmaceuticals INC. | $320.99 | 2022-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $248.84 | 2021-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $240.05 | 2021-2024 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $224.48 | 2021-2022 | |
| Indivior INC. | $207.72 | 2021-2024 | Perseris |
| E.R. Squibb & Sons, L.L.C. | $144.54 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $57.81 | 2021 | |
| Corium, LLC | $52.64 | 2022-2023 | Azstarys |
| Janssen Biotech, INC. | $7.75 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fitz Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.